Related references
Note: Only part of the references are listed.Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial
Stephen R. D. Johnston et al.
LANCET ONCOLOGY (2023)
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
N. Harbeck et al.
ANNALS OF ONCOLOGY (2021)
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer
Kevin Kalinsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age
Martine Piccart et al.
LANCET ONCOLOGY (2021)
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
Stephen R. D. Johnston et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial
Masakazu Toi et al.
LANCET ONCOLOGY (2020)
Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration
Samuel C. Y. Leung et al.
HISTOPATHOLOGY (2019)
Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019
H. J. Burstein et al.
ANNALS OF ONCOLOGY (2019)
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
J. A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UKTACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial
David Cameron et al.
LANCET ONCOLOGY (2017)
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
N. Masuda et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival
Ann H. Partridge et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials
Meredith M. Regan et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial
Tsutomu Takashima et al.
LANCET ONCOLOGY (2016)
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
J. A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
An International Ki67 Reproducibility Study
Mei-Yin C. Polley et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Efficacy of oral tegafur-uracil (UFT) as adjuvant therapy as compared with classical cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in early breast cancer: a pooled analysis of two randomized controlled trials (N•SAS-BC 01 trial and CUBC trial)
Yasuo Ohashi et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in post-operative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study
Y. Park et al.
BRITISH JOURNAL OF CANCER (2009)
Oral Uracil and Tegafur Compared With Classic Cyclophosphamide, Methotrexate, Fluorouracil As Postoperative Chemotherapy in Patients With Node-Negative, High-Risk Breast Cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial
Toru Watanabe et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: Nationwide survival data in Korea - A report from the Korean Breast Cancer Society
Sei Hyun Ahn et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients:: The FNCLCC PACS 01 trial
Henri Roche et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer
Stephen E. Jones et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial
KAA Fox et al.
LANCET (2005)
Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28
EP Mamounas et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: A pooled analysis of six randomized controlled trials
S Noguchi et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Share Paper
